Malnourished HCC Patients Associated with Highest Inpatient Mortality Among GI Cancers

Cholankeril, Rosann; Copelin, Eddie L.; Yoo, Eric R.; Siddique, Osama; Gadiparthi, Chiranjeevi; Khan, Muhammad Ali; Perumpail, Brandon J; Perumpail, Ryan B.; Hu, Menghan; Cholankeril, George; Ahmed, Aijaz

doi:10.1016/s0016-5085(17)31269-6

Cited by 1 publication

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A total of six studies reported admission-related payer costs [ 63 , 75 , 76 , 99–101 ]; however, all of these were in selected populations, including patients with malnutrition [ 100 ], patients born 1945–1965 [ 99 ], patients who underwent radiofrequency ablation [ 101 ], patients who received palliative care [ 63 ], or patients with HCC combined with patients with hepatobiliary diseases [ 75 ]. Admission-related hospital charges were described in five publications [ 41 , 59 , 66 , 67 , 102 ]; in the most recent data in a nonselected population (year 2011), mean charges per admission were US$59,686 [ 59 ].…”

Section: Resultsmentioning

confidence: 99%

“…A total of 13 studies reported inpatient length of stay [ 17 , 41 , 50 , 57 , 59 , 63 , 66 , 67 , 75 , 76 , 99 , 100 , 102 ], of which four studies described nonselected cohorts and reported trends over time [ 59 , 66 ], by etiology [ 102 ], and by age or payer [ 50 ]. The typical inpatient length of stay was approximately 6 days.…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Epidemiologic, humanistic and economic burden of hepatocellular carcinoma in the USA: a systematic literature review

et al. 2020

View full text Add to dashboard Cite

Aim: To describe the epidemiologic, humanistic and economic burdens of hepatocellular carcinoma (HCC) in the USA. Materials & methods: Studies describing the epidemiology and economic burden from national cohorts, any economic models, or any humanistic burden studies published 2008–2018 were systematically searched. Results: HCC incidence was 9.5 per 100,000 person-years in most recent data, but was ∼100-times higher among patients with hepatitis/cirrhosis. Approximately a third of patients were diagnosed with advanced disease. Patients with HCC experienced poor quality of life. Direct costs were substantial and varied based on underlying demographics, disease stage and treatment received. Between 25–77% of patients did not receive surgical, locoregional or systemic treatment. Conclusion: Better treatments are needed to extend survival and improve quality of life for patients with HCC.

show abstract